Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Exondys 51 Market Forecast Highlighting Growth From $ Billion To $ Billion
The expansion observed during the historic period was driven by the absence of curative therapies for DMD, a traditional dependence on supportive care, early-stage research into antisense technologies, incentives designed to encourage drug development for rare diseases, and the emergence of initial regulatory approvals.
Growth during the forecast period is driven by progress in molecular genetics, the broadening of personalized neuromuscular care, the expansion of newborn screening programs, higher research funding for DMD, and the proliferation of specialized neurology centers. Key trends shaping this period encompass the development of exon-skipping therapies, the widening scope of targeted DMD treatments, the increasing uptake of genetic-based medicines, an emphasis on decelerating disease progression, and a growing focus on long-term therapeutic management.
Download A Free Sample Report For Comprehensive Market Insights:
Exondys 51 Market Growth Drivers And Industry Catalysts
The escalating prevalence of genetic disorders is anticipated to drive expansion in the exondys 51 market in the coming period. These disorders stem from anomalies or mutations in an individual’s DNA or genetic makeup, and their increasing incidence results from factors such as technological progress in medicine, shifting population demographics, and enhanced diagnostic capabilities and public awareness. Exondys 51 (eteplirsen) addresses genetic conditions by facilitating exon 51 skipping within the dystrophin gene, which enables the production of a shortened yet functional dystrophin protein, thereby slowing muscle deterioration. As an example, the National Health Service, a UK government body, reported in July 2024 that around 70,000 people in the UK are affected by muscular dystrophy (MD) or a related condition, with Duchenne MD being the most common. Approximately 100 boys are diagnosed with Duchenne MD annually, and roughly 2,500 individuals in the UK are living with the condition at any given moment. Consequently, the growing burden of genetic disorders is fueling expansion in the exondys 51 market.
Exondys 51 Market Driver: Impact Of Rising Healthcare Investments On The Growth Of The Market
Increasing financial commitments to healthcare are projected to support growth in the exondys 51 market moving forward. Such investments involve directing monetary resources toward healthcare entities, technologies, services, or innovations, and they are on the rise due to heightened demand for managing chronic diseases among aging populations, along with funding for advanced tools like telemedicine that enhance care delivery. These investments bolster exondys 51 by supporting research, clinical trials, and technologies such as exon-skipping, which enable treatment of Duchenne muscular dystrophy, and by improving patient access through programs and infrastructure. For instance, the Office for National Statistics, a UK government department, noted in May 2024 that healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, a substantial increase compared to the 0.9% growth recorded in 2022. Thus, rising healthcare investments are propelling the exondys 51 market forward.
Exondys 51 Market Segment Analysis And Revenue Opportunities
The exondys 51 market covered in this report is segmented –
1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use
Exondys 51 Market Trends Influencing Long-Term Demand
Key players in the exondys 51 market are prioritizing safety improvements and more precise patient selection, including revisions to ELEVIDYS prescribing information to reduce liver-related risks and confirm appropriate patient eligibility. ELEVIDYS is Sarepta Therapeutics’ AAV-based micro-dystrophin gene therapy (delandistrogene moxeparvovec), intended to restore dystrophin expression in individuals with Duchenne muscular dystrophy (DMD). As an example, in November 2025, the U.S. FDA, a federal agency based in the United States, approved a revised label for ELEVIDYS that includes a boxed warning for acute serious liver injury and acute liver failure, while also restricting its use to ambulatory patients aged four years and older. This update mandates weekly liver-function testing during the first three months after infusion, requires corticosteroid administration before and after dosing, and recommends that patients stay within close proximity to a qualified healthcare facility for at least two months—all measures designed to enhance safety monitoring and improve patient outcomes.
Exondys 51 Market Leading Players Shaping Industry Direction
Major companies operating in the exondys 51 market are Sarepta Therapeutics
Access The Complete Exondys 51 Market Report:
Exondys 51 Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the exondys 51 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the exondys 51 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model